Table 2.
Summary of the anti-inflammation and antilipidemic effect of curcumin.
| Outcome | Included experiments | N | MD | I 2% | P value | Egger's test |
|---|---|---|---|---|---|---|
| (1) Effect on plasma lipid level | ||||||
| Tc | 12 [8–9, 17–18, 29–30, 32–33] | 179 | -1.005 (-1.885, -0.124) | 76.20% | 0.025 | 0.226 |
| TG | 12 [8–9, 17–18, 29–30, 32–33] | 179 | -0.045 (-0.088, -0.002) | 0.20% | 0.042 | 0.063 |
| HDL | 9 [17–18, 29–30, 32] | 109 | -0.087 (-0.235, 0.060) | 9.20% | 0.245 | 0.975 |
| LDL-c | 7 [18, 29–30, 32–33] | 108 | -0.523 (-0.896, -0.149) | 89.10% | 0.006 | 0.081 |
| (2) Effect on plasma inflammatory responses | ||||||
| TNF-α# | 6 [18, 29–31] | 88 | -56.641 (-86.848, -26.433) | 92.30% | <0.001 | 0.036∗ |
| IL-6 | 8 [17–18, 29–30] | 89 | -10.687 (-23.705, 2.331) | 90.40% | 0.108 | 0.753 |
| IL-1β | 4 [17, 31] | 41 | -5.089 (-8.559, -1.619) | 0.00% | 0.004 | 0.894 |
Tc: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL-c: low-density lipoprotein cholesterol; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; IL-1β: interleukin-1β; N: total number of animals in the study; #Two pairwise experiments were omitted; ∗Publication bias existed. P < 0.05 represents the significant difference.